KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases.

$14.79  +0.47 (3.28%)
As of 06/24/2021 15:59:41 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  Bermuda
IPO date:  05/24/2018
Outstanding shares:  32,322,276
Average volume:  517,884
Market cap:   $461,885,324
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    G5269C101
ISIN:        BMG5269C1010
Sedol:      BD0MGM0
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.61
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy